CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive / Household & Personal Products industry as a multinational manufacturer and marketer of consumer and professional products. Its fiscal 2026 net sales reached $6.7 billion, generated by roughly 9,200 employees across approximately 25 countries and sold into about 95 markets. The consumer portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while the professional side sells under Purell, CloroxPro, and Clorox Healthcare.

In April 2026, Clorox completed the acquisition of GOJO Industries, which expanded its health and hygiene exposure and deepened its business-to-business presence. The Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026; Clorox purchased P&G’s 20% interest, and Glad retained core intellectual property licenses on a royalty-free basis.

Profitability signals are mixed. The 8.7% net margin is positive and consistent with a staples business that earns recurring demand, but it is not unusually wide for the sector. The reported ROE of -1,893.5% is an extreme outlier and does not reflect operational returns in a useful way. It points instead to a deeply negative or very small shareholders’ equity base, likely magnified by debt, buybacks, or accounting charges. Because ROE is distorted, margin and cash generation—not equity returns—are the cleaner lenses for assessing competitive durability. On the customer side, Walmart accounted for 26% of FY2026 net sales, and the five largest customers represented about half of consolidated sales. That concentration gives key retailers meaningful bargaining leverage and is a structural constraint on pricing power.

Financial posture

Clorox currently carries a $10.4 billion market cap, trades at a P/E of 17.8, and has a low beta of 0.54. The valuation is in line with a mature defensive stock, while the beta confirms the stock has historically moved less than the broader market. The 8.7% net margin remains intact, but fiscal 2026 was clearly a difficult year: diluted EPS fell 26%, with organic sales and earnings both declining.

The -1,893.5% ROE is the most striking financial figure. A negative ROE of that magnitude typically means the company has negative book equity, so traditional ROE-based comparisons are unreliable here. Investors should focus on leverage, interest coverage, free cash flow, and the trajectory of margins rather than on equity-return metrics. Near-term price action also shows stress: at $85.595, CLX sits below its 50-day EMA of $95.77, and its RSI of 30.7 is approaching technically oversold territory. None of these figures, on their own, indicate direction—they simply describe a stock that has moved lower into a compressed valuation range.

Strategic priorities & outlook

Clorox’s most recent 10-K frames its agenda around four planks of the IGNITE strategy: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Operationally, management is focused on three execution priorities.

First, it aims to complete and optimize a new enterprise resource planning (ERP) system as part of a broader digital transformation designed to drive long-term efficiencies across supply chain, digital commerce, innovation, and brand building. The filing notes that ERP transition timing actually pulled some sales into fiscal 2025, contributing to fiscal 2026’s weaker comparison, so the ERP is both a long-term efficiency driver and a near-term source of noise.

Second, Clorox plans to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build resilience and deliver more consistent, profitable growth. Third, it is advancing health and hygiene expansion and portfolio optimization, including integrating GOJO and growing professional and institutional markets. The GOJO integration will likely be a key variable for margins and revenue mix over the next several quarters.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox is exposed to input-cost volatility in resins, pulp, chemicals, packaging, and energy-derived freight costs. These commodities can move with oil prices, supply-chain disruptions, and trade policy, so tariff shifts or freight squeezes can affect gross margins even when end demand is stable. Currency risk also matters: sales in roughly 95 markets create translation exposure for a U.S. dollar-reported income statement.

Regulatory exposure is inherent to the sector. Cleaning, disinfecting, food-contact, and personal-care products face EPA, FDA, and state-level chemical regulations, as well as evolving consumer preferences around sustainability, plastic packaging, and ingredient transparency. Retail concentration compounds these pressures, because large customers can demand pricing concessions and private-label alternatives. The professional/healthcare segment, now larger after GOJO, adds sensitivity to hospital, institutional, and office hygiene spending cycles.

Recent developments

The latest news flow is mixed and focused on income and ownership positioning rather than operations. On September 21, 2026, 247wallst.com published “Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer,” a sign that the market is scrutinizing payout sustainability in a year when EPS dropped 26%. The same day, defenseworld.net reported that MAC Alpha Capital Management LP bought shares of CLX. Two days earlier, on September 19, 2026, 247wallst.com flagged Clorox in “These 6 Massive Dividend Yields May Be Too Good to Be True,” again pointing to dividend sustainability questions. On September 18, 2026, defenseworld.net noted that Baird Financial Group Inc. cut its CLX position. Taken together, these headlines show divided institutional sentiment rather than a clear directional read.

Earnings behavior & post-earnings drift

Clorox has beaten the official consensus in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 9.6%. Over the five trading days following each of those reports, the stock has averaged a +1.67% gain, classified as an “up” post-earnings drift. That historical tendency, however, masks large individual reactions.

The most recent quarter, reported August 3, 2026, delivered EPS of $1.66 against an estimate of $1.64, a modest 1.2% beat, yet the stock rose 6.52% the next day and 9.61% over the following five sessions. By contrast, the April 30, 2026 quarter beat by a wider 5.8%—$1.64 versus $1.55—but sold off 9.67% the next day and 4.49% over five days. The February 3, 2026 report was a 2.8% miss ($1.39 vs. $1.43 estimate), yet the stock rose 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter beat by 3.9% ($0.85 vs. $0.818) but drifted -4.08% over the following week.

This pattern suggests that CLX’s post-earnings moves are driven at least as much by guidance, margin commentary, and macro sentiment as by the headline EPS beat or miss. The next scheduled report is November 3, 2026 after the close, with a consensus EPS estimate of $1.11.

For a deeper dive into whether the current valuation compression reflects a durable reset or a temporary dislocation, investors should examine the full institutional verdict on CLX, including consensus target aggregates, recent rating changes, and forward estimate revision trends.